GlucoBites Cookies (Gynura Procumbens) for Glycemic Control and Prevention of Diabetic Foot Ulcer Risk in Type 2 Diabetes

NCT ID: NCT07151833

Last Updated: 2025-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-20

Study Completion Date

2026-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized controlled trial is to learn if GlucoBites functional cookies containing Gynura procumbens can help improve blood sugar control and lower the risk of diabetic foot ulcers in adults with type 2 diabetes.

The main questions are:

* Do GlucoBites cookies lower fasting blood glucose and HbA1c?
* Do GlucoBites cookies improve insulin resistance and vascular health?
* Can GlucoBites reduce early signs that may lead to diabetic foot ulcers?

Researchers will compare:

* Intervention group: participants will eat 4 GlucoBites cookies every day for 12 weeks.
* Control group: participants will continue standard diabetes care without GlucoBites.

Participants will:

* Visit the community health center for blood tests and foot health checks.
* Be monitored for blood sugar, insulin resistance, lipid profile, and vascular function.
* Be assessed for early risk of diabetic foot ulcer development.

This study will help determine if a functional food innovation can support diabetes care and prevent complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 diabetes mellitus is a chronic condition associated with serious complications, including neuropathy and diabetic foot ulcers. Many people in Indonesia still struggle with poor blood sugar control despite standard treatments. This highlights the need for safe, affordable, and culturally acceptable nutritional strategies.

This study is testing GlucoBites, a functional cookie made with Gynura procumbens, a traditional medicinal plant with potential glucose-lowering and vascular protective properties. Researchers want to see if adding GlucoBites to daily care can improve blood sugar control and reduce early risk factors linked to diabetic foot ulcer development.

The study will help determine whether functional food innovation can be integrated into community-based diabetes management and offer a preventive approach to reduce long-term complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Diabetic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This randomized controlled trial uses a parallel assignment model with two study arms. Participants will be randomly allocated to either the intervention group receiving GlucoBites functional cookies containing Gynura procumbens or the control group receiving standard diabetes care. Both groups will be followed simultaneously for 12 weeks.
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Participants in both arms receive visually identical cookies. The experimental cookies contain Gynura procumbens extract, while the control cookies do not. Packaging, appearance, weight, and flavor are matched. Randomization codes are held by an independent pharmacist/allocator; care providers and outcomes assessors are blinded to group assignment. Unblinding will occur only after database lock or for safety reasons.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Cookies (without Gynura procumbens)

Participants receive 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor but do not contain Gynura procumbens.

Group Type PLACEBO_COMPARATOR

Control Cookies (without Gynura procumbens)

Intervention Type DIETARY_SUPPLEMENT

Participants consume 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor to the GlucoBites cookies but do not contain Gynura procumbens.

GlucoBites (with Gynura procumbens)

Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract.

Group Type EXPERIMENTAL

GlucoBites (with Gynura procumbens)

Intervention Type DIETARY_SUPPLEMENT

Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GlucoBites (with Gynura procumbens)

Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract.

Intervention Type DIETARY_SUPPLEMENT

Control Cookies (without Gynura procumbens)

Participants consume 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor to the GlucoBites cookies but do not contain Gynura procumbens.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Functional Cookies with Gynura procumbens Placebo cookies

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 20-70 years.
* Diagnosed with type 2 diabetes mellitus (T2DM) based on ADA criteria.
* HbA1c ≥ 7%.
* At risk of diabetic foot ulcer (ABI \< 0.9 or early neuropathy signs).
* Willing to consume study cookies and comply with study protocol.
* Provided written informed consent.

Exclusion Criteria

* Current use of herbal supplements or functional foods containing Gynura procumbens.
* Presence of active diabetic foot ulcer or severe infection.
* Severe cardiovascular, renal (eGFR \< 30 mL/min/1.73 m²), or hepatic impairment.
* Pregnancy or breastfeeding.
* Known allergy to ingredients in study cookies.
* Participation in another clinical trial within the last 3 months.
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Andina Setyawati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andina Setyawati

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Public Health Centre of Campagaloe

Bantaeng, South Sulawesi, Indonesia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Indonesia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andina Setyawati, Dr

Role: CONTACT

+628121521639

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Baucaya Baucaya, BSN

Role: primary

+6282393444557

Syamsul Kamar, BSN

Role: backup

+62 82394971423

Related Links

Access external resources that provide additional context or updates about the study.

https://jppres.com/jppres/pdf/vol13/jppres24.2112_13.3.836.pdf

Original research article reporting the antidiabetic effects of Gynura procumbens on pancreatic histopathology via caspase family expression in diabetic rat models, published in the Journal of Pharmacy \& Pharmacognosy Research (2025).

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

02209/UN4.22/PT.01.03/2025

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

GlucoBites-DM2-2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.